Top

Published in:

Open Access 01-12-2014 | Research

Serum B7-H4 expression is a significant prognostic indicator for patients with gastric cancer

Authors: Hongbing Shi, Mei Ji, Jun Wu, Qi Zhou, Xiaodong Li, Zhengguang Li, Xiao Zheng, Bing Xu, Weiqing Zhao, Changping Wu, Jingting Jiang

Published in: World Journal of Surgical Oncology | Issue 1/2014

Abstract

Background

B7-H4 is a novel B7 ligand that plays an important role in the T cell-mediated immune response as a negative regulator. Previous studies have suggested the aberrant expression of membrane B7-H4 in tumor cells. The aim of this study is to determine the expression levels of preoperative soluble B7-H4 (sB7-H4) in circulation and to investigate the correlations between sB7-H4 levels and clinicopathological parameters as well as the survival rate of patients with gastric cancer.

Methods

Blood specimens from 132 patients with gastric cancer and 63 healthy volunteers were analyzed by sandwich enzyme-linked immunosorbent assay.

Results

Median concentrations of sB7-H4 in patients with gastric cancer were significantly higher than those in healthy volunteers (16.85 versus 10.46 ng/mL; P = 0.008). Median levels of sB7-H4 were significantly correlated with tumor size, lymph node metastasis, the depth of tumor invasion and tumor-node-metastasis classification (P = 0.002, P = 0.001, P = 0.041 and P <0.001, respectively), but not with sex, age, tumor location or histological subtype (all P >0.05). Additionally, the overall survival rate was significantly lower in patients with high sB7-H4 levels when compared with low sB7-H4 levels (50.0% versus 77.3%, χ² = 10.78, P = 0.001). Moreover, multivariate analysis demonstrated that the risk of death was significantly higher in patients with high sB7-H4 levels than in those with low sB7-H4 levels (P = 0.039).

Conclusions

sB7-H4 is a valuable blood marker for predicting the progression and prognosis of patients with gastric cancer.

Available only for authorised users

Hartgrink HH, Jansen EP, van Grieken NC, van de Velde CJ: Gastric cancer. Lancet. 2009, 374: 477-490. 10.1016/S0140-6736(09)60617-6.CrossRefPubMed

Yeh JM, Kuntz KM, Ezzati M, Goldie SJ: Exploring the cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer in China in anticipation of clinical trial results. Int J Cancer. 2009, 124: 157-166. 10.1002/ijc.23864.PubMedCentralCrossRefPubMed

Bouche O, Ychou M, Burtin P, Bedenne L, Ducreux M, Lebreton G, Baulieux J, Nordlinger B, Martin C, Seitz JF, Tigaud JM, Echinard E, Stremsdoerfer N, Milan C, Rougier P: Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial (8801). Ann Oncol. 2005, 16: 1488-1497. 10.1093/annonc/mdi270.CrossRefPubMed

Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ, Participants MT: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006, 355: 11-20. 10.1056/NEJMoa055531.CrossRefPubMed

Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM, Martenson JA: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001, 345: 725-730. 10.1056/NEJMoa010187.CrossRefPubMed

Nashimoto A, Nakajima T, Furukawa H, Kitamura M, Kinoshita T, Yamamura Y, Sasako M, Kunii Y, Motohashi H, Yamamoto S: Randomized trial of adjuvant chemotherapy with mitomycin, Fluorouracil, and Cytosine arabinoside followed by oral Fluorouracil in serosa-negative gastric cancer: Japan Clinical Oncology Group 9206–1. J Clin Oncol. 2003, 21: 2282-2287. 10.1200/JCO.2003.06.103.CrossRefPubMed

Orditura M, De Vita F, Muto P, Vitiello F, Murino P, Lieto E, Vecchione L, Romano A, Martinelli E, Renda A, Ferraraccio F, Del Genio A, Ciardiello F, Galizia G: Adjuvant chemoradiotherapy in patients with stage III or IV radically resected gastric cancer: a pilot study. Arch Surg. 2010, 145: 233-238. 10.1001/archsurg.2010.2.CrossRefPubMed

Greenwald RJ, Freeman GJ, Sharpe AH: The B7 family revisited. Annu Rev Immunol. 2005, 23: 515-548. 10.1146/annurev.immunol.23.021704.115611.CrossRefPubMed

Konishi J, Yamazaki K, Azuma M, Kinoshita I, Dosaka-Akita H, Nishimura M: B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res. 2004, 10: 5094-5100. 10.1158/1078-0432.CCR-04-0428.CrossRefPubMed

10.

Simon I, Zhuo S, Corral L, Diamandis EP, Sarno MJ, Wolfert RL, Kim NW: B7-h4 is a novel membrane-bound protein and a candidate serum and tissue biomarker for ovarian cancer. Cancer Res. 2006, 66: 1570-1575. 10.1158/0008-5472.CAN-04-3550.CrossRefPubMed

11.

Zang X, Thompson RH, Al-Ahmadie HA, Serio AM, Reuter VE, Eastham JA, Scardino PT, Sharma P, Allison JP: B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc Natl Acad Sci U S A. 2007, 104: 19458-19463. 10.1073/pnas.0709802104.PubMedCentralCrossRefPubMed

12.

Prasad DV, Richards S, Mai XM, Dong C: B7S1, a novel B7 family member that negatively regulates T cell activation. Immunity. 2003, 18: 863-873. 10.1016/S1074-7613(03)00147-X.CrossRefPubMed

13.

Sica GL, Choi IH, Zhu G, Tamada K, Wang SD, Tamura H, Chapoval AI, Flies DB, Bajorath J, Chen L: B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity. 2003, 18: 849-861. 10.1016/S1074-7613(03)00152-3.CrossRefPubMed

14.

Zang X, Loke P, Kim J, Murphy K, Waitz R, Allison JP: B7x: a widely expressed B7 family member that inhibits T cell activation. Proc Natl Acad Sci U S A. 2003, 100: 10388-10392. 10.1073/pnas.1434299100.PubMedCentralCrossRefPubMed

15.

Aunoble B, Sanches R, Didier E, Bignon YJ: Major oncogenes and tumor suppressor genes involved in epithelial ovarian cancer (review). Int J Oncol. 2000, 16: 567-576.PubMed

16.

Carreno BM, Collins M: BTLA: a new inhibitory receptor with a B7-like ligand. Trends Immunol. 2003, 24: 524-527. 10.1016/j.it.2003.08.005.CrossRefPubMed

17.

Nicosia SV, Bai W, Cheng JQ, Coppola D, Kruk PA: Oncogenic pathways implicated in ovarian epithelial cancer. Hematol Oncol Clin North Am. 2003, 17: 927-943. 10.1016/S0889-8588(03)00056-X.CrossRefPubMed

18.

Wang S, Chen L: Co-signaling molecules of the B7-CD28 family in positive and negative regulation of T lymphocyte responses. Microbes Infect. 2004, 6: 759-766. 10.1016/j.micinf.2004.03.007.CrossRefPubMed

19.

Zou W, Chen L: Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol. 2008, 8: 467-477. 10.1038/nri2326.CrossRefPubMed

20.

Awadallah NS, Shroyer KR, Langer DA, Torkko KC, Chen YK, Bentz JS, Papkoff J, Liu W, Nash SR, Shah RJ: Detection of B7-H4 and p53 in pancreatic cancer: potential role as a cytological diagnostic adjunct. Pancreas. 2008, 36: 200-206. 10.1097/MPA.0b013e318150e4e0.CrossRefPubMed

21.

Jiang J, Zhu Y, Wu C, Shen Y, Wei W, Chen L, Zheng X, Sun J, Lu B, Zhang X: Tumor expression of B7-H4 predicts poor survival of patients suffering from gastric cancer. Cancer Immunol Immunother. 2010, 59: 1707-1714. 10.1007/s00262-010-0900-7.CrossRefPubMed

22.

Krambeck AE, Thompson RH, Dong H, Lohse CM, Park ES, Kuntz SM, Leibovich BC, Blute ML, Cheville JC, Kwon ED: B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc Natl Acad Sci U S A. 2006, 103: 10391-10396. 10.1073/pnas.0600937103.PubMedCentralCrossRefPubMed

23.

Kryczek I, Wei S, Zhu G, Myers L, Mottram P, Cheng P, Chen L, Coukos G, Zou W: Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma. Cancer Res. 2007, 67: 8900-8905. 10.1158/0008-5472.CAN-07-1866.CrossRefPubMed

24.

Simon I, Katsaros D, Rigault de la Longrais I, Massobrio M, Scorilas A, Kim NW, Sarno MJ, Wolfert RL, Diamandis EP: B7-H4 is over-expressed in early-stage ovarian cancer and is independent of CA125 expression. Gynecol Oncol. 2007, 106: 334-341. 10.1016/j.ygyno.2007.03.035.CrossRefPubMed

25.

Sun Y, Wang Y, Zhao J, Gu M, Giscombe R, Lefvert AK, Wang X: B7-H3 and B7-H4 expression in non-small-cell lung cancer. Lung Cancer. 2006, 53: 143-151. 10.1016/j.lungcan.2006.05.012.CrossRefPubMed

26.

Tringler B, Zhuo S, Pilkington G, Torkko KC, Singh M, Lucia MS, Heinz DE, Papkoff J, Shroyer KR: B7-h4 is highly expressed in ductal and lobular breast cancer. Clin Cancer Res. 2005, 11: 1842-1848. 10.1158/1078-0432.CCR-04-1658.CrossRefPubMed

27.

Zheng Y, Katsaros D, Shan SJ, de la Longrais IR, Porpiglia M, Scorilas A, Kim NW, Wolfert RL, Simon I, Li L, Feng Z, Diamandis EP: A multiparametric panel for ovarian cancer diagnosis, prognosis, and response to chemotherapy. Clin Cancer Res. 2007, 13: 6984-6992. 10.1158/1078-0432.CCR-07-1409.CrossRefPubMed

28.

Sobin LH: Wittekind CH International Union Against Cancer: TNM Classification of Malignant Tumors. 2002, New York: Wiley-Liss, 6

29.

Podojil JR, Miller SD: Targeting the B7 family of co-stimulatory molecules: successes and challenges. BioDrugs. 2013, 27: 1-13.PubMedCentralCrossRefPubMed

30.

Thompson RH, Zang X, Lohse CM, Leibovich BC, Slovin SF, Reuter VE, Cheville JC, Blute ML, Russo P, Kwon ED, Allison JP: Serum-soluble B7x is elevated in renal cell carcinoma patients and is associated with advanced stage. Cancer Res. 2008, 68: 6054-6058. 10.1158/0008-5472.CAN-08-0869.PubMedCentralCrossRefPubMed

31.

Arigami T, Uenosono Y, Hirata M, Hagihara T, Yanagita S, Ishigami S, Natsugoe S: Expression of B7-H4 in blood of patients with gastric cancer predicts tumor progression and prognosis. J Surg Oncol. 2010, 102: 748-752. 10.1002/jso.21722.CrossRefPubMed

Title: Serum B7-H4 expression is a significant prognostic indicator for patients with gastric cancer
Authors: Hongbing Shi
Mei Ji
Jun Wu
Qi Zhou
Xiaodong Li
Zhengguang Li
Xiao Zheng
Bing Xu
Weiqing Zhao
Changping Wu
Jingting Jiang
Publication date: 01-12-2014
Publisher: BioMed Central
Published in: World Journal of Surgical Oncology / Issue 1/2014
Electronic ISSN: 1477-7819
DOI: https://doi.org/10.1186/1477-7819-12-188

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Serum B7-H4 expression is a significant prognostic indicator for patients with gastric cancer

Abstract

Background

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2014

Prognostic significance of WT1 expression in soft tissue sarcoma

Three cases of laparoscopic total gastrectomy with intracorporeal esophagojejunostomy for gastric cancer in remnant stomach

Safety and efficacy of transurethral laser therapy for bladder cancer: a systematic review and meta-analysis

Breast carcinoma with choriocarcinomatous features: a case report and review of the literature

A case of extraperitoneal stoma-associated internal hernia after abdominoperineal resection

Preoperative thrombocytosis is a significant unfavorable prognostic factor for patients with resectable non-small cell lung cancer